# US 2025/0145681 A1 · Fusion proteins for the treatment of cardiometabolic diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145681 A1
- Document ID: US20250145681A1
- Status: Published application
- Kind: A1
- Application number: 18/950,933
- Filed: 2024-11-18
- Published: 2025-05-08
- Earliest claimed: 2022-12-05
- Assignees: Shattuck Labs, Inc.
- Applicants: Shattuck Labs, Inc.
- Inventors: Taylor SCHREIBER; George FROMM
- Web page: https://patentgrep.com/patent/US20250145681A1

## CPC

- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- C07K 14/605: Glucagons
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 9/00: Drugs for disorders of the cardiovascular system
- C07K 14/50: Fibroblast growth factor [FGF]
- C07K 14/575: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695)
- C07K 14/62: Insulins
- C07K 14/645: Secretins
- C07K 14/72: for hormones {(for neuromediators C07K14/70571)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/31: fusions, other than Fc, for prolonged plasma life, e.g. albumin
- C07K 2319/50: containing protease site
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure relates to, inter alia, compositions and pharmaceutical composition s, including heterologous chimeric proteins that find use, inter alia, in the treatment of diabetes, obesity, or metabolic syndrome.

## Claims

### Claim at position 1

-278. (canceled)

### Claim 279

A method of treating or preventing diabetes or obesity in a subject in need thereof, the method comprising administering to the subject a chimeric protein having a general structure of:
N terminus-(a)-(b)-(c)-C terminus,
wherein:
(a) is a first domain comprising a glucagon-like peptide-1 (GLP-1) receptor agonist comprising an amino acid sequence of SEQ ID NO: 91 or variant thereof comprising one or two amino acid mutations with respect to an amino acid sequence of amino acid sequence of SEQ ID NO: 91, wherein the GLP-1 receptor agonist is resistant to DPP4 degradation;
(b) is a linker adjoining the first domain and a second domain wherein the linker comprises a hinge-CH2-CH3 Fc domain; and
(c) is the second domain comprising glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) antagonist comprising an amino acid sequence of selected from SEQ ID NO: 97, or variant thereof comprising one or two amino acid mutations with respect to an amino acid sequence of amino acid sequence selected from SEQ ID NO: 97, wherein the GIPR antagonist comprises a Proline (P) residue at position 3 with respect to SEQ ID NO: 97.

### Claim 280 (depends on 279)

The method of claim 279, wherein the GLP-1 receptor agonist comprises the amino acid sequence of SEQ ID NO: 91.

### Claim 281 (depends on 280)

The method of claim 280, wherein the GLP-1 receptor agonist is capable of:
binding a GLP-1 receptor,
regulating pancreatic β-cell growth and survival, gastric emptying, and appetite,
stimulating and/or increasing insulin secretion, and/or inhibiting and/or decreasing glucagon secretion, and/or
resisting degradation caused by dipeptidyl peptidase IV (DPP4).

### Claim 282 (depends on 279)

The method of claim 279, wherein the GIPR antagonist comprises an amino acid sequence of SEQ ID NO: 97.

### Claim 283 (depends on 282)

The method of claim 282, wherein the GIPR modulator is capable of:
binding a GIP receptor (GIPR),
inhibiting the GIPR, and/or
modulating the GIPR on the surface of the endocrine pancreas.

### Claim 284 (depends on 279)

The method of claim 279, wherein the hinge-CH2-CH3 Fc domain is derived from IgG1 or IgG4.

### Claim 285 (depends on 284)

The method of claim 284, wherein
the IgG1 is human IgG1, or
the IgG4 is human IgG4.

### Claim 286 (depends on 279)

The method of claim 279, wherein the hinge-CH2-CH3 Fc domain comprises an amino acid sequence that is at least 95% identical to the amino acid sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 76.

### Claim 287 (depends on 279)

The method of claim 279, wherein the linker further comprises one or more joining linkers, such joining linkers independently selected from SEQ ID NOs: 4 to 50, 92 and 113.

### Claim 288 (depends on 279)

The method of claim 279, wherein the chimeric protein comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 95.

### Claim 289 (depends on 279)

The method of claim 279, wherein the linker further comprises one or two protease-cleavable polypeptide linkers.

### Claim 290 (depends on 289)

The method of claim 289, wherein the protease-cleavable polypeptide linkers have amino acid sequences that are independently selected from HSSKLQ (SEQ ID NO: 70), GPLGVRG (SEQ ID NO: 71), IPVSLRSG (SEQ ID NO: 72), VPLSLYSG (SEQ ID NO: 73), SGESPAYYTA (SEQ ID NO: 74), and RFRS (SEQ ID NO: 75).

### Claim 291 (depends on 289)

The method of claim 289, wherein the protease-cleavable polypeptide linkers are C-terminal to the first domain and/or N-terminal to the second domain.

### Claim 292

A method of treating or preventing diabetes or obesity in a subject in need thereof, the method comprising administering to the subject an isolated polynucleotide encoding a chimeric protein having a general structure of:
N terminus-(a)-(b)-(c)-C terminus,
wherein:
(a) is a first domain comprising a glucagon-like peptide-1 (GLP-1) receptor agonist comprising an amino acid sequence of SEQ ID NO: 91 or variant thereof comprising one or two amino acid mutations with respect to an amino acid sequence of amino acid sequence of SEQ ID NO: 91, wherein the GLP-1 receptor agonist is resistant to DPP4 degradation;
(b) is a linker adjoining the first domain and a second domain wherein the linker comprises a hinge-CH2-CH3 Fc domain; and
(c) is the second domain comprising glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) antagonist comprising an amino acid sequence of selected from SEQ ID NO: 97, or variant thereof comprising one or two amino acid mutations with respect to an amino acid sequence of amino acid sequence selected from SEQ ID NO: 97, wherein the GIPR antagonist comprises a Proline (P) residue at position 3 with respect to SEQ ID NO: 97.

### Claim 293 (depends on 292)

The method of claim 292, wherein the GLP-1 receptor agonist comprises the amino acid sequence of SEQ ID NO: 91.

### Claim 294 (depends on 292)

The method of claim 292, wherein the GIPR antagonist comprises an amino acid sequence of SEQ ID NO: 97.

### Claim 295 (depends on 292)

The method of claim 292, wherein the chimeric protein comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 95.

### Claim 296 (depends on 292)

The method of claim 292, wherein the isolated polynucleotide is a modified mRNA (mmRNA) that comprises at least one chemically modified nucleoside selected from pseudouridine, N1-methylpseudouridine, 5-methylcytosine, and 5-methoxyuridine.

### Claim 297 (depends on 292)

The method of claim 292, wherein the isolated polynucleotide comprises one or more of a 5′-cap, a poly A tail, a 5′ UTR and a 3′ UTR.

### Claim 298 (depends on 292)

The method of claim 292, wherein the isolated polynucleotide is formulated as a lipid nanoparticle (LNP), a lipoplex, or a liposome.
